drugset / Trial / NCT03270085

Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption

NCT03270085

RandomizedParallel-groupTriple-blindOther

Summary

To compare with a randomized trial (n=15 per treatment group), effects of colesevelam and placebo treatment, on colonic transit, bowel functions, permeability and tight junction expression in rectosigmoid mucosa of IBS-D with Bile Acid Malabsorption.

Timeline

Start
2017-12-07
Primary completion
2019-05-31
Completion
2019-05-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Colesevelam Other / unclassified 1875 mg Oral